Oslo, Norway, November 17, 2020 - Vaccibody AS, a clinical-stage
biopharmaceutical company dedicated to the discovery and development of novel
immunotherapies, today announced its third quarter 2020 results.

The third quarter 2020 report will be available at
https://www.vaccibody.com/financial-reports-and-presentations/ 

Contact for Vaccibody:
CEO Michael Engsig
Vaccibody AS
info@vaccibody.com  


About Vaccibody 

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the
discovery and development of novel immunotherapies. The Company is using the
Vaccibody technology platform to generate best-in-class therapeutics against
cancers and infectious diseases with a high unmet medical need. 

Vaccibody is developing cutting-edge, targeted DNA vaccines for clinical use,
based on a deep understanding of immunological principles. Vaccibody's vaccines
specifically targets antigens to Antigen Presenting Cells (APC), which are
essential for inducing rapid, strong and specific immune responses and elicit
efficacious clinical responses. By intelligent design, Vaccibody's vaccines can
be tailored to induce the desired immune response profile correlating with
protection for each specific disease with any given antigen. Hence, the
Vaccibody vaccine platform has the potential to address many disease areas with
a high unmet medical need such as cancer and infectious diseases. Vaccibody has
collaborations with Roche and Genentech, and Nektar Therapeutics and will pursue
further collaborations and strategic partnerships to maximize the value of its
technology platform.

Vaccibody's shares are traded on Merkur Market, a trading platform operated and
wholly owned by Oslo Børs ASA, the Oslo Stock Exchange. The ticker code is
VACC-ME.

Further information about the Company may be found at http://www.vaccibody.com